Citibank: Goli Pharmaceuticals-B (01672) ASC30 Phase IIa data further shows best-in-class potential and reaffirms the “buy/high risk” rating

The Zhitong Finance App learned that Citibank released a research report saying that it is expected that the stock price of Goli Pharmaceutical-B (01672) will respond positively; reaffirming the “buy/high risk” rating, the target price is HK$32. Citi believes that the release of positive data from the US Phase IIa study on the oral GLP-1 drug asc30 for the treatment of obesity has further demonstrated the best potential of ASc30 in its class and strengthened confidence in future cooperation.

According to the report, Cully Pharmaceuticals released positive data from the US Phase IIa study on the use of the oral GLP-1 drug asc30 to treat obesity. At week 13 of the 20 mg, 40 mg, and 60 mg dose groups of ASC30, the weight loss after placebo correction was 5.4%, 7%, and 7.7%, respectively. Among them, the efficacy of the medium/high dose group was better than that expected (weight loss > 6.5%). No liver safety signals were found in the study, and there was no increase in ALT/AST/TBL. Under the weekly incremental dosage regimen, the drug was well tolerated; only 7.3%, 7.5%, and 0% of ASC30 discontinued treatment due to adverse events in the 20 mg, 40 mg, and 60 mg dose groups, which was the best among similar drugs. The incidence of vomiting was 22%, 25%, and 30% in the 20 mg, 40 mg, and 60 mg dose groups, respectively, better than the 56% reported by Orforglipron in its phase IB study of weekly incremental doses. The company plans to submit data to the US FDA in the first quarter of 2026 and apply to end the Phase II meeting.